Cambridge Nutritional SciencesFRA:RVKA EBITDA Margin % is -1.71% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 84.44% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cambridge Nutritional Sciences EBITDA Margin % Related Terms
Cambridge Nutritional Sciences EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RVKA vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences (FRA:RVKA) has a EBITDA Margin % of -1.71% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #127 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 15.6%.
Is Cambridge Nutritional Sciences' EBITDA Margin % too high?
Cambridge Nutritional Sciences' current EBITDA Margin % is -1.71%. Based on the distribution chart, Cambridge Nutritional Sciences ranks #127 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #127 out of 816 companies for EBITDA Margin %. This places Cambridge Nutritional Sciences in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current EBITDA Margin % is -1.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Possible Value Trap. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 32.5% below its estimated fair value. The current EBITDA Margin % is -1.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current EBITDA Margin % is -1.71% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences Business Description
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 